MEAP
MEAP (2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine) is a NEDD9-STAT3 modulator. MEAP disrupts NEDD9-STAT3 interaction, driving STAT3 Y705 dephosphorylation. MEAP induces G2/M phase arrest. MEAP can be used for the research of anaplastic thyroid cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C25H33N7O
- Masse moléculaire:447.58
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
STAT3 |
In Vitro
MEAP potently inhibits AURKA, AURKB, AURKC, and FAK kinases in a cell-free biochemical assay[1].
MEAP potently induces centrosome-mediated microtubule nucleation in THJ-16T anaplastic thyroid cancer cells[1].
MEAP (1-5 μM) increases pericentriolar material accumulation at less active centrosomes during interphase and early mitosis in THJ-16T anaplastic thyroid cancer cells with normal centrosome numbers[1].
MEAP significantly increases pericentriolar material recruitment to supernumerary centrosomes in interphase THJ-11T and THJ-16T anaplastic thyroid cancer cells[1].
MEAP (300 nM; 48 h) preferentially induces spindle multipolarity by activating inactive supernumerary centrosomes in ALDH+ THJ-11T and THJ-16T anaplastic thyroid cancer cells, without changing centrosome amplification or fragmentation rates[1].
MEAP (300 nM; 48 h) induces selective G2/M phase arrest in ALDH+ THJ-16T anaplastic thyroid cancer cells, without selective apoptosis or senescence relative to ALDH− cells[1].
MEAP (300 nM; 96 h) reduces the ALDH+ anaplastic thyroid cancer cell population by over 80% in THJ-11T, THJ-16T, and 8505c cells via selective growth inhibition, with a dose-dependent response in THJ-16T cells[1].
MEAP (0.1-1 μM) pretreatment dose-dependently suppresses tumorsphere formation in THJ-11T, THJ-16T, and 8505c anaplastic thyroid cancer cells, attenuating stemness[1].
MEAP (100 nM; 5-60 min) selectively induces rapid dephosphorylation of STAT3Y705 in ALDH+ THJ-16T anaplastic thyroid cancer cells, while nonselectively reducing phosphorylated Aurora-A levels[1].
MEAP (100 nM; 10 min) disrupts the NEDD9-STAT3 protein interaction in ALDH+ THJ-16T anaplastic thyroid cancer cells within 10 minutes[1].
MEAP (100 nM; 15 min) reduces colocalization of NEDD9 and phosphorylated STAT3Y705 in ALDH+ THJ-16T anaplastic thyroid cancer cells, altering their intracellular localization[1].
MEAP (100 nM; 24 h) induces centrosome microtubule nucleation and γ-tubulin accumulation in ALDH+ THJ-16T anaplastic thyroid cancer cells in a NEDD9-STAT3-dependent manner[1].
MEAP reduces chromosome missegregation in ALDH+ THJ-16T anaplastic thyroid cancer cells in a NEDD9-STAT3-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Sorted ALDH+ and ALDH- THJ-11T and THJ-16T anaplastic thyroid cancer cells
-
Concentration:300 nM
-
Incubation Time:48 h
-
Result:Reduced the percentage of inactive mitotic centrosomes in ALDH+ THJ-11T and THJ-16T cells.
Increased spindle multipolarity (32% in ALDH+ cells vs. 8% in ALDH- cells) and decreased pseudobipolar spindles in ALDH+ cells.
Did not alter the frequency of centrosome amplification or centrosome fragmentation.
-
Cell Line:Sorted ALDH+ and ALDH- THJ-16T anaplastic thyroid cancer cells
-
Concentration:300 nM
-
Incubation Time:1 h; 24 h; 48 h
-
Result:Induced G2/M phase accumulation in ALDH+ cells (reaching 15% of cells in G2/M by 48 hours) but not in ALDH- cells.
Did not cause selective apoptosis or senescence in ALDH+ cells relative to ALDH- cells.
-
Cell Line:Sorted ALDH+ and ALDH- THJ-16T anaplastic thyroid cancer cells
-
Concentration:100 nM
-
Incubation Time:5 min; 15 min; 30 min; 45 min; 60 min
-
Result:Rapidly depleted pSTAT3-Y705 levels in ALDH+ cells within 5 minutes, with no change in ALDH- cells.
Reduced phosphorylated Aurora-A levels nonselectively in both ALDH+ and ALDH- cells.
Did not alter total STAT3, total Aurora-A, or NEDD9 protein levels.
-
Cell Line:ALDH+ THJ-16T anaplastic thyroid cancer cells
-
Concentration:100 nM
-
Incubation Time:15 min
-
Result:Reduced colocalization of NEDD9 and pSTAT3-Y705, with Pearson's R value decreasing from 0.83 (DMSO) to 0.33.
Decreased cytoplasmic pSTAT3-Y705 staining and redistributed NEDD9 from the perinuclear region.
In Vivo
MEAP (30 mg/kg; i.p.; triweekly; 4 weeks) drives a robust antitumor response with ~4-fold tumor volume reduction relative to controls and no apparent host toxicity in a subcutaneous ATC mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID (female, 6- to 8-week-old, orthotopic model with 5 × 105 8505c ATC cells injected into right thyroid gland)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; 3 total doses on day 15, 17, and 20
-
Result:Eliminated detectable ALDH1-positive cell clusters in tumors.
Increased the γ-tubulin weak/strong centrosome symmetry ratio from 0.29 to 0.74.
Increased the percentage of mitotic cells with multipolar spindles to ~15%.
Reduced the percentage of mitotic cells with missegregated chromosomes to ~40%.
-
Animal Model:NOD-SCID (female, 6- to 8-week-old, subcutaneous model with 8505c ATC cells implanted subcutaneously, treatment initiated when tumors reached 40-80 mm3)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; triweekly for 4 weeks
-
Result:Resulted in a ~4-fold reduction in tumor volume compared with vehicle controls.
Outperformed Taxol in suppressing ATC tumor growth.
Caused no detectable toxicity or body weight loss.
Chemical Information
-
Masse moléculaire 447.58
-
Formule C25H33N7O
-
SMILES
C[C@@H]1[C@H](C[C@H]2C[C@@H]1C2(C)C)NC3=C4N=CNC4=NC(NC5=CC=C(C=C5)N6CCOCC6)=N3
-
Synonyms
2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- MEAP
- 2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine
- STAT
- anaplastic thyroid cancer
- NEDD9-STAT3 interaction
- pericentriolar accumulation
- STAT3 Y705
- spindle multipolarity
- G2/M phase arrest
- centrosome microtubule nucleation
- NEDD9-STAT3 signaling axis
- supernumerary centrosomes
- THJ-16T
- Inhibitor
- inhibitor
- inhibit